



ASX Announcement

11 February 2026

ECS Enters German Distribution Partnership with Nimbus Health; OzSun Launch Imminent

ECS Botanics Holdings Ltd (ASX: ECS) ("ECS" or the "Company"), a leading medicinal cannabis company, is pleased to advise that the Company has secured a strategic distribution partnership with Nimbus Health GmbH, one of Germany's leading cannabis distributors with national pharmacy reach.

Highlights:

- **ECS signs strategic distribution agreement with Nimbus Health, a leading German medicinal cannabis distributor**
- **Nimbus holds the necessary authorisations to import and distribute ECS-branded medicinal cannabis in Germany, with first sales targeted for April 2026**
- **OzSun products will be distributed nationally via Nimbus's extensive pharmacy network including pharmacy onboarding and professional education channels**
- **ECS to enter Europe's largest cannabis market, valued at ~€500m in 2025, with a value-focused, organic product range targeting budget-conscious patients**
- **ECS to launch premium ECS-grown Terphogz strains in Germany under its exclusive brand license later in 2026**
- **Expansion into Germany aligns with ECS's international growth strategy and leverages existing production capacity at no material additional cost**

This non-exclusive partnership provides ECS with a platform to formally enter Europe's largest medicinal cannabis market under its own brands, following its EU-GMP accreditation and completion of German market entry requirements.

Nimbus will take responsibility for import, warehousing, distribution and support trade-facing brand activation and pharmacy engagement.

In line with ECS's successful domestic strategy, OzSun Germany will be positioned as a high-quality, value-focused brand designed to serve the budget-conscious segment of the market. This sun grown range leverages ECS's EU-GMP certified operations and organic credentials, providing a compliant and cost-effective product for patients.



The launch of OzSun coincides with increased scrutiny of GMP/GDP compliance in the German market, raising the bar for fully compliant supply chains. This has created a higher barrier to entry and favours fully compliant, GMP-certified producers like ECS, whose vertically integrated operations and quality credentials meet the highest international standards.

Initially, patients will be able to access two OzSun strains of ECS-supplied organic, EU-GMP medicinal cannabis dried flower via Nimbus Health's distribution network.

The German launch forms part of ECS's broader strategy to expand its successful branded B2C and hybrid distribution model into selected international markets. Production for Germany will be supplied from ECS's existing cultivation capacity, with no material additional production costs required.

To support further expansion in Germany, ECS will launch a curated range of ECS-grown cultivars under its exclusive Terphogz brand licence in the second half of 2026. These genetics, selected in collaboration with Terphogz following a multi-year pheno-hunting program utilising Terphogz seeds, have been curated specifically for the premium segment of the European market and will complement the value positioning of the OzSun line. ECS will cultivate these strains at its Australian facilities, using the same organic and sustainable practices that underpin the success of its OzSun and Avani range.

ECS Botanics Managing Director, Nan-Maree Schoerie, said:

"Following the successful launch of ECS's own brands in Australia, partnering with Nimbus is a key step in the expansion of ECS's international footprint. We're entering Europe's largest cannabis market with a proven brand, a compliant platform and a respected distribution partner. Nimbus provides us with immediate access to a broad pharmacy network without the need for significant additional infrastructure. We've tailored our strategy to current market dynamics, offering a value-focused product with a quality pedigree."

"What differentiates ECS is our commitment to quality, organic certification, Australian provenance with full PIC/S GMP manufacturing capability and fast-growing brand equity. With production capacity in place and the right partner on board, we're confident that our offer will resonate strongly in Germany, where patients and regulators are increasingly demanding reliable, affordable, compliant medicinal cannabis backed by a proven track record."

Further updates on the launch of OzSun and Terphogz products in Germany will be provided in the following quarter.

Authorised for release by Nan-Maree Schoerie, Managing Director

-ENDS-

Investors and Media

Tim Dohrmann, NWR Communications
P: +61 468 420 846
E: tim@nwrccommunications.com.au



About ECS Botanics Holdings Ltd

ECS Botanics Holdings Ltd (ASX: ECS) is an Australian medicinal cannabis cultivator and manufacturer located in Northwest Victoria. ECS utilises progressive and innovative cultivation methodologies to produce quality medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. Licensed by the Australian Therapeutic Goods Administration to manufacture GMP (equivalent to PIC/S, EU agencies are all PIC/S members) certified products, ECS has become a leading provider of high quality, affordable medicinal cannabis.